Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.58 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343745 | 1.00 | COMT (0.58) | COMTHPSEPLAUMAPK14PRSS12 | |
| SCHEMBL14381770 | 0.89 | COMT (0.66) | COMTHPSEPLAUPRSS12MMP2 | |
| SCHEMBL8769684 | 0.88 | COMT (0.70) | COMTHPSEPRSS12MMP2MMP9 | |
| SCHEMBL8770496 | 0.85 | HPSE (0.61) | HPSEPRSS12MMP2MMP9MMP8 | |
| SCHEMBL14381555 | 0.85 | COMT (0.70) | COMTHPSEPRSS12MMP2MMP9 | |
| SCHEMBL14381860 | 0.85 | COMT (0.70) | COMTHPSEPRSS12MMP2MMP9 | |
| SCHEMBL14381881 | 0.85 | COMT (0.70) | COMTHPSEPRSS12MMP2MMP9 | |
| SCHEMBL14381528 | 0.84 | COMT (0.60) | COMTHPSEPLAUPRSS12MMP2 | |
| SCHEMBL14381920 | 0.84 | COMT (0.60) | COMTHPSEPLAUPRSS12MMP2 | |
| SCHEMBL14381916 | 0.84 | COMT (0.60) | COMTHPSEPLAUPRSS12MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3515904-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | Centre Leon Berard (FR) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | COMT 4582/4885HPSE 4674/4885PLAU 4853/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | COMT 4185/4885HPSE 4099/4885PLAU 4297/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | COMT 4185/4885HPSE 4099/4885PLAU 4297/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | COMT 4177/4885HPSE 4034/4885PLAU 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.